- Conditions
- Idiopathic Intracranial Hypertension
- Interventions
- Presendin, Placebo
- Drug
- Lead sponsor
- Invex Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Miami, Florida • Minneapolis, Minnesota + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pre-diabetes, Type 2 Diabetes
- Interventions
- Exenatide, Sitagliptin, Glimepiride
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Gestational Diabetes
- Interventions
- Exenatide
- Drug
- Lead sponsor
- Maisa N. Feghali, MD
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Diabetes Mellitus
- Interventions
- Exantide with Dapagliflozin, Exentide, Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 695 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 61 more
- Conditions
- Type 2 Diabetes
- Interventions
- Byetta (exenatide), Symlin (pramlintide)
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide, long acting release, exenatide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 24
- States / cities
- Encino, California • La Jolla, California • San Diego, California + 21 more
- Conditions
- Type 2 Diabetes
- Interventions
- placebo, exenatide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 40
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 550,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Type 2 Diabetes
- Interventions
- Insulin Glargine, Metformin, Prandial insulin, Exenatide
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 12
- States / cities
- San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more
- Conditions
- Obesity
- Interventions
- Exenatide, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Saint Paul, Minnesota
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide, Pioglitazone
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exenatide (AC2993), Insulin glargine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 21
- States / cities
- San Diego, California • San Mateo, California • Fort Myers, Florida + 18 more
- Conditions
- Polycystic Ovary Syndrome, Obesity
- Interventions
- Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA, Dapagliflozin plus Glucophage (MET ER), Phentermine /Topiramate (PHEN/ TPM) ER
- Drug
- Lead sponsor
- Woman's
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 119 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Human Immunodeficiency Virus Infection, Diabetes Mellitus
- Interventions
- extended-release exenatide
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- exenatide, taspoglutide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 87
- States / cities
- Haleyville, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more
- Conditions
- Type 2 Diabetes
- Interventions
- Exenatide
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Lixisenatide (AVE0010), Pen auto-injector, Exenatide, Prefilled pen injector, Metformin
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 639 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Obesity
- Interventions
- Exenatide, Placebo, Dietary counseling
- Drug · Behavioral
- Lead sponsor
- Jody Dushay
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 249 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Peripheral Neuropathy
- Interventions
- Exenatide, Glargine
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Type 2 Diabetes
- Interventions
- ITCA 650, ITCA placebo
- Drug · Other
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 102 more
- Conditions
- Type 2 Diabetes
- Interventions
- Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 2
- States / cities
- Chula Vista, California • Orlando, Florida
- Conditions
- Obesity, Impaired Glucose Tolerance
- Interventions
- exenatide, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 25 Years to 60 Years · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide Once Weekly, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 14,752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 139
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 124 more
- Conditions
- Type 2 Diabetes
- Interventions
- ITCA 650, ITCA placebo
- Drug · Other
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 4,156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 34
- States / cities
- Chandler, Arizona • Hayward, California • Long Beach, California + 28 more